The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Association of semaglutide with risk of suicidal ideation in a real-world cohort
Open accessAbstract
Concerns over reports of suicidal ideation associated with semaglutide treatment, a glucagon-like peptide 1 receptor (GLP1R) agonist medication for type 2 diabetes (T2DM) and obesity, has led to investigations by European regulatory agencies. In this retrospective cohort study of electronic health records from the TriNetX Analytics Network, we aimed to assess the associations of semaglutide with suicidal ideation compared to non-GLP1R agonist anti-obesity or anti-diabetes medications. The hazard ratios (HRs) and 95% confidence intervals (CIs) of incident and recurrent suicidal ideation were calculated for the 6-month follow-up by comparing propensity score-matched patient groups. The study population included 240,618 patients with overweight or obesity who were prescribed semaglutide or non-GLP1R agonist anti-obesity medications, with the findings replicated in 1,589,855 patients with T2DM. In patients with overweight or obesity (mean age 50.1 years, 72.6% female), semaglutide compared with non-GLP1R agonist anti-obesity medications was associated with lower risk for incident (HR = 0.27, 95% CI = 0.200.32-0.600.36) and recurrent (HR = 0.44, 95% CI = 0.32-0.60) suicidal ideation, consistent across sex, age and ethnicity stratification. Similar findings were replicated in patients with T2DM (mean age 57.5 years, 49.2% female). Our findings do not support higher risks of suicidal ideation with semaglutide compared with non-GLP1R agonist anti-obesity or anti-diabetes medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in the retrospective cohort study using TriNetX Analytics Network electronic health records, semaglutide significantly lowered the risk of both new (HR, 0.27; 95% CI, 0.20 to 0.32) and recurrent (HR, 0.44; 95% CI, 0.32 to 0.60) suicidal ideation compared to non-GLP-1 RAs anti-obesity treatments [80].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [80]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas several observational studies have generated varied findings on of the effect of GLP-1 receptor agonists on the risk of suicidal ideation, self-harm, and suicide, which may be a result of methodological limitations in these studies.8 9 10 11 12 13”
From Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“and recurrent (HR, 0.44; 95% CI, 0.32 to 0.60) suicidal ideation compared to non-GLP-1 RAs anti-obesity treatments [80].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [80]
In the citing paper
“Among AOMs currently approved, tirzepatide 15 mg and semaglutide 2.4mg have the greatest efficacy (Figure 1).65,67,87”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Glucagon-like peptide 1 receptor (GLP1R) agonists initially developed as anti-diabetes medications are highly effective for weight loss 8,9 .”
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management
Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2021-001952 · Cited by 318
Sam, A. H., Salem, V., & Ghatei, M. A. (2011) · Journal of Obesity · doi:10.1155/2011/432607 · Cited by 230
Worldwide suicide mortality trends (2000-2019): A joinpoint regression analysis
Ilić, M., & Ilić, I. (2022) · World Journal of Psychiatry · doi:10.5498/wjp.v12.i8.1044 · Cited by 220
Castaneda, D., Popov, V. B., Wander, P., & Thompson, C. C. (2019) · Obesity Surgery · doi:10.1007/s11695-018-3493-4 · Cited by 186
The critical distinction between suicidal ideation and suicide attempts
Klonsky, E. D., Dixon‐Luinenburg, T., & May, A. M. (2021) · World Psychiatry · doi:10.1002/wps.20909 · Cited by 181
Cheung, B. M. Y., Cheung, T. T., & Samaranayake, N. R. (2013) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098613489721 · Cited by 163
Research works printed but not linked: 2
- Findlay, S. Health policy brief: the FDA’s sentinel initiative. Health Affairs www.healthaffairs.org/do/10.1377/hpb20150604.936915/ (2015). · DOI
- John Mann, J. & Currier, D. Insights from Neurobiology of Suicidal Behavior (CRC Press, 2012).
Cited by
Sorted by citations
Lingvay, I., Cohen, R. V., Roux, C. W. L., & Sumithran, P. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01210-8 · Cited by 433
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Wang, L., Xu, R., Kaelber, D. C., & Berger, N. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.21305 · Cited by 304
Self-citationMapping the effectiveness and risks of GLP-1 receptor agonists
Xie, Y., Choi, T., & Al-Aly, Z. (2025) · Nature Medicine · doi:10.1038/s41591-024-03412-w · Cited by 300
Ludwig, R. J., Anson, M., Zirpel, H., Thaçi, D., Olbrich, H., Bieber, K., Kridin, K., Dempfle, A., Curman, P., Zhao, S. S., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1516126 · Cited by 299
Metadata
- Authors
- Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R.
- Affiliations
- Case Western Reserve University (US)
- National Institutes of Health (US)
- MetroHealth (US)
- Corresponding author
- Volkow, Nora D.
- Xu, Rong
- Venue
- Nature Medicine
- Published
- 2024-01
- Volume
- 30
- Issue
- 1
- Pages
- 168-176
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC11034947
- OpenAlex
- W4390616108
- Cited by
- 248
- References
- 34
- Citations by year
- 2026: 72 · 2025: 91 · 2024: 84
- FWCI
- 81.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Case Comprehensive Cancer Center, Case Western Reserve University (CA043703)
- National Institute on Alcohol Abuse and Alcoholism (R01AA029831)
- National Institute on Aging (R01AG061388, R56AG062272, RF1AG076649, R01AG057557)
- National Cancer Institute (CA043703, CA2332216, P30CA043703, R25CA221718)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (DP2HD084068)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Keywords
- semaglutide, suicidal ideation, GLP-1 receptor agonists, type 2 diabetes, obesity, anti-obesity drugs, drug safety, adverse drug reactions, real-world evidence
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Retrospective Studies, Anti-Obesity Agents, Overweight, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
